Moleculin Biotech
MBRX
MBRX
20 hedge funds and large institutions have $4.44M invested in Moleculin Biotech in 2023 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Holders
20
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$1.78M | |
| 2 | +$35.7K | |
| 3 | +$27.6K | |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$11K |
| 5 |
Renaissance Technologies
New York
|
+$5.19K |
Top Sellers
| 1 | -$116K | |
| 2 | -$13K | |
| 3 | -$3.94K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.94K |
| 5 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$2.7K |